ABSTRACT TEMPLATE: CHECKLIST AND INSTRUCTIONS

Company name: Chemomab * Website: www.chemomab.com *

CEO name: Adi Mor *

CATEGORY: Biotech/Pharma

- Immunology and Inflammation Reclaim top Priorities in BioPharma: Driver and Opportunities

o Executive Summary / Investment Rational Briefly describe the company's technology or therapeutic focus; the market opportunity, progress made to date, key partnerships or joint ventures, investment to date; and management strengths.

Chemomab is a clinical-stage company focused on the discovery and development of innovative therapeutics for fibrotic and inflammatory diseases with high unmet needs. Based on the pivotal role of the soluble protein CCL24 in promoting fibrosis and inflammation, we have developed nebokitug, a monoclonal antibody designed to bind and block CCL24 activity. Nebokitug demonstrated the potential to treat multiple severe and life-threatening fibrotic and inflammatory diseases.

o Core Technology What is the technology, its uniqueness, and its value proposition?

Nebokitug, is a first-in-class humanized monoclonal antibody that attenuates the basic function of CCL24 as a regulator of major inflammatory and fibrotic pathways. We have demonstrated that nebokitug interferes with the underlying biology of inflammation and fibrosis through a novel and differentiated mechanism of action. Nebokitug recently showed positive phase 2 data in primary sclerosing cholangitis and a phase 3 pivotal study is in preparations.

o Product Profile/Pipeline Briefly describe the company's product/pipeline, status, and market potential. Discuss milestones, potential collaborations, and partnerships.

Chemomab has reported positive results from three clinical trials of nebokitug in patients, including the most recent Phase 2 trial in PSC patients, a rare obstructive and cholestatic liver disease. Positive topline results from both the double-blind portion of this trial were positive demonstrating the drug was safe and efficient in improving multiple biomarkers that represent disease activity. The strong phase 2 data and concurrent FDA advice pave the way for a phase 3 pivotal study in PSC.

What's Next?

Chemomab is planning to report data from the open label extension part of the phase 2 PSC study in Q1,2025. The open label extension is expected to provide additional data on long term safety and durability of effects during 48 weeks of treatment with nebokitug.